In re: Nexium: Judge Young Denies Defendants’ Motions for a Directed Verdict
Last week, the Nexium district court ruled on defendants’ motions seeking judgment as a matter of law. As we previously reported in several earlier posts (click here to see our prior coverage), In re: Nexium is the first pay-for-delay case to go to trial since the Supreme Court’s Federal Trade Commission v. Actavis decision.
The Nexium plaintiffs have asserted a novel pay-for-delay theory: that AstraZeneca agreed to accept a reduced settlement payment from Teva in a separate patent infringement litigation involving Prilosec in exchange for Teva’s agreement to delay its launch of Nexium’s generic competitor. According to plaintiffs, this reduced payment constitutes a large, unexplained payment within the meaning of Actavis. The theory involves not only Teva but also generic manufacturer Ranbaxy, which also settled a patent infringement case involving generic Nexium.
Although focusing on that novel issue is interesting for blog posts, in their motions defendants smartly focused the court’s attention on the more run-of-the-mill questions facing the court: Can plaintiffs show conspiracy, causation and antitrust injury? After all, steering a district court towards a well-trodden path on these issues is much easier than convincing the court to take the bigger leap on a novel question: Does the alleged consideration here fall within Actavis? Defendants probably thought that there was a chance that Judge Young might latch on to one of these issues and resolve the case on a traditional antitrust issue or two. However, Judge Young chose not to engage in a lengthy discussion on any of these issues and, with the exception of a motion addressed to an alleged conspiracy between Teva and Ranbaxy, simply denied defendants’ motions saying that there are several “prudential reasons” why the case should go to a jury, and noted that concerns about “jumping too quickly” prompted him to deny the directed verdict bids.
It therefore appears that we will see a jury verdict on the novel issue raised in In re: Nexium and probably post-verdict rulings by district and appellate courts.